#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Tillman Gerngross Email
Co-Founder & CEO . Adagio Therapeutics
How to contact Tillman Gerngross
Join and see Tillman's contact info for free!Current Roles
Employees:
91Revenue:
$17.5MAbout
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic by the end of 2020.Adagio Therapeutics Address
1601 Trapelo RoadWaltham, MA
United States